GlassScriptPhysician profile
Jessica Ivey
NPI 1124096136
$5,640.80
in general payments reported to CMS, 2019-2025
49 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $187 · 2021: $11.91 · 2022: $198 · 2023: $627 · 2024: $1,843 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.04 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $764.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $594.60 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $474.27 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $469.34 | 2024-2025 | |
| Lilly USA, LLC | $463.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $379.37 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $372.07 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $248.18 | 2019-2025 | |
| Edwards Lifesciences Corporation | $178.21 | 2023-2025 | |
| Astellas Pharma US INC | $158.59 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $141.99 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $118.71 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $101.03 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $100.13 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
| Merck Sharp & Dohme LLC | $84.43 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Ivey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.